Alterity Therapeutics obtains new US patent for compounds for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease
Melbourne, Australia and SAN FRANCISCO, January 6, 2022 / PRNewswire / – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to the development of disease-modifying therapies for neurodegenerative diseases, announced today the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity.
The composition of matter patent, titled “Compounds and Methods of Treating Diseases,” received priority review by the USPTO. The patent covers more than 80 new compounds and guarantees the exclusivity of a new class of iron chaperones designed to redistribute the excess iron involved in many neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.
“We continue to identify new drug candidates to expand our portfolio and protect our therapeutic approach to combat neurodegeneration,” said David stamler, MD, CEO, Alterity. “With the granting of this and another patent on the composition of matter last year, we are laying a solid foundation as a leader in targeting iron for potential disease modification therapy for d ‘important neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. “
The patent will provide Alterity with exclusivity over the compounds claimed in the patent until 2041, thus providing a solid foundation for the development and commercialization of drugs in the major neurodegenerative diseases.
In addition to the United States, the company is seeking patent protection in other jurisdictions.
About Parkinson’s disease
Parkinson’s disease (PD) belongs to a group of conditions called motor system disorders, which cause the body to move involuntarily or uncontrollably. The precise cause of PD is unknown, but some cases are hereditary while others are believed to result from a combination of genetic and environmental factors that trigger the disease. In PD, brain cells are damaged or die in the part of the brain that produces dopamine, a chemical needed to produce smooth, focused movement. The four main symptoms of PD are tremors, stiffness, slowing of spontaneous and automatic movements, and disturbances in balance. Other symptoms may include difficulty swallowing, chewing, or speaking; emotional changes; urinary problems or constipation; dementia or other cognitive problems; tired; and sleep problems. Almost one million people in the United States and more than 10 million people worldwide are living with PD. About 60,000 Americans are diagnosed with PD each year.
About Alzheimer’s disease
Alzheimer’s disease is a progressive neurological disorder that causes shrinkage (atrophy) of the brain and death of brain cells. Alzheimer’s disease is the most common cause of dementia – a continuing decline in mental, behavioral and social skills that affects a person’s ability to function independently. About 5.8 million people in United States 65 and over live with Alzheimer’s disease. Of these, 80% are 75 and over. Of the roughly 50 million people with dementia worldwide, between 60% and 70% are believed to have Alzheimer’s disease. Medicines can temporarily improve or slow the progression of symptoms, but there is no treatment that cures Alzheimer’s disease or changes the disease process in the brain. In later stages of the disease, complications from severe loss of brain function, such as dehydration, malnutrition or infection, lead to death.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical-stage biotechnology company dedicated to creating an alternative future for people living with neurodegenerative diseases. The Company’s main asset, ATH434, has the potential to treat various parkinsonian disorders. Alterity also has an extensive drug discovery platform generating patentable chemical compounds to intervene in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, UNITED STATES. For more information, please visit the Company’s website at www.alteritytherapeutics.com.
Authorization & Additional Information
This advertisement has been authorized by David stamler, CEO of Alterity Therapeutics Limited.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has attempted to identify such forward-looking statements by using such words. that “expects”, “intends”, “hopes”, “anticipates”, “believes”, “could”, “could”, “evidence” and “estimates” and other expressions similar, but these words are not the exclusive means of identifying such statements.
Significant factors that could cause actual results to differ materially from those indicated by these forward-looking statements are described in the sections headed “Risk Factors” in the Company’s filings with the SEC, including its annual report on most recent on Form 20-F as well as as reports on Form 6-K, including, but not limited to: but not limited to: but not limited to ATH434, and any other statements which are not facts historical. These statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to difficulties or delays in the financing, development, testing, regulatory approval, production and marketing of the products. drug components of the Company, including, but not limited to ATH434, uncertainties relating to the impact of the novel coronavirus (COVID-19) pandemic on the business, operations and employees of the Company, the the Company’s ability to secure additional future sources of funding, unexpected adverse side effects or inadequate therapeutic efficacy of drug compounds, including, but not limited to ATH434, which could slow or prevent the development in the product market, the uncertainty of obtaining patent protection for the Company’s intellectual property or trade secrets, the uncertainty of enforcing the success of the Company’s patent rights and the uncertainty of the Company’s freedom to operate.
Any forward-looking statement we make in this press release is based solely on information currently available to us and speaks only as of the date on which it is made. We assume no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
 National Institute of Health: Neurological Disorders and Stroke, Parkinson’s Disease Information Page;
 Parkinson’s Foundation: understanding Parkinson’s disease
 Mayo Clinic: Alzheimer’s disease
SOURCE Alterity Therapeutics Limited